Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment

Table 6 Prognostic factors of overall survival by multivariable Cox regression analysis

	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age (within 70 yr)	0.867	0.603–1.246	0.440	-	-	-
Male	1.216	0.802–1.842	0.357	-	-	-
Etiology (HBV)	1.313	0.809–2.133	0.271	-	-
BCLC stage B	0.667	0.459–0.969	0.033	0.601	0.405–0.891	0.011
Portal vein thrombosis	1.677	1.092–2.575	0.018	1.133	0.674–1.903	0.638
Extrahepatic spread	0.740	0.509–1.074	0.113	0.671	0.419–1.076	0.098
AFP (> 400 ng/mL)	1.282	0.893–1.839	0.178	1.370	0.936–2.006	0.105
ECOG Performance status 1	0.752	0.488–1.158	0.196	1.042	0.636–1.708	0.869
Group A vs Group B	0.703	0.431–1.147	0.159	0.658	0.398–1.088	0.103
Group A vs Group C	0.431	0.281–0.663	< 0.001	0.407	0.253–0.654	< 0.001
Sorafenib administration period (second half vs first half)	1.205	0.840–1.728	0.311	-	-	-

AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; HBV: Hepatitis B virus; ECOG: Eastern Cooperative Oncology Group.